APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Life Science CDMO

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Life Science CDMO Market Outlook and Growth Opportunities 2026

1 May 2026192 pages

Choose your research edition.

Industry ResearchLife Science CDMO Industry Research Report 2026128 pages · $2,950 USDIndustry Growth & TrendsGlobal Life Science CDMO Industry Growth and Trends Forecast to 2032111 pages · $3,450 USDMarket StructureGlobal Life Science CDMO Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Life Science CDMO Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Life Science CDMO Market Analysis and Forecast 2026-2032222 pages · $4,950 USD

Market perspective

The global Life Science CDMO market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Life Science CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Life Science CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Life Science CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Life Science CDMO market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Life Science CDMO market include Lonza Group, Thermo Fisher Scientific, Catalent, WuXi Biologics, Samsung Biologics, Siegfried, Fujifilm Diosynth Biotechnologies, Lars Petersen and Recipharm, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Life Science CDMO market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Life Science CDMO and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Life Science CDMO revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Life Science CDMO market.

Life Science CDMO Segment by Company

Lonza Group

Thermo Fisher Scientific

Catalent

WuXi Biologics

Samsung Biologics

Siegfried

Fujifilm Diosynth Biotechnologies

Lars Petersen

Recipharm

Boehringer Ingelheim

MilliporeSigma

Aenova Group

AGC Parma Chemicals

GenScript

Novartis

Sai Life Sciences

Life Science CDMO Segment by Type

Active Pharmaceutical Ingredient (API) CDMO

Biologics CDMO

Finished Dosage Form (FDF) CDMO

Others

Life Science CDMO Segment by Application

Pharmaceutical

Clinical

Research

Life Science CDMO Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Life Science CDMO status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Life Science CDMO key companies, revenue, market share, and recent developments.

3. To split the Life Science CDMO breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Life Science CDMO market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Life Science CDMO significant trends, drivers, influence factors in global and regions.

6. To analyze Life Science CDMO competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Life Science CDMO market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Life Science CDMO and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Life Science CDMO.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Life Science CDMO industry.

Chapter 3: Detailed analysis of Life Science CDMO company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Life Science CDMO in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Life Science CDMO in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Life Science CDMO Industry Trends Table 2. Life Science CDMO Industry Drivers Table 3. Life Science CDMO Industry Opportunities and Challenges Table 4. Life Science CDMO Industry Restraints Table 5. Global Life Science CDMO Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Life Science CDMO Revenue Share by Company (2021-2026) Table 7. Global Life Science CDMO Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Life Science CDMO Key Company Manufacturing Base & Headquarters Table 9. Global Life Science CDMO Company, Product Type & Application Table 10. Global Life Science CDMO Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Life Science CDMO by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Active Pharmaceutical Ingredient (API) CDMO Table 15. Significant Companies of Biologics CDMO Table 16. Significant Companies of Finished Dosage Form (FDF) CDMO Table 17. Significant Companies of Others Table 18. Global Life Science CDMO Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global Life Science CDMO Sales Value by Type (2021-2026) & (US$ Million) Table 20. Global Life Science CDMO Sales Value by Type (2027-2032) & (US$ Million) Table 21. Global Life Science CDMO Sales Value Share by Type (2021-2026) Table 22. Global Life Science CDMO Sales Value Share by Type (2027-2032) Table 23. Significant Companies of Pharmaceutical Table 24. Significant Companies of Clinical Table 25. Significant Companies of Research Table 26. Global Life Science CDMO Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Life Science CDMO Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global Life Science CDMO Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global Life Science CDMO Sales Value Share by Application (2021-2026) Table 30. Global Life Science CDMO Sales Value Share by Application (2027-2032) Table 31. Global Life Science CDMO Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Life Science CDMO Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global Life Science CDMO Sales Value Share by Region (2021-2026) Table 34. Global Life Science CDMO Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global Life Science CDMO Sales Value Share by Region (2027-2032) Table 36. Global Life Science CDMO Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Life Science CDMO Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global Life Science CDMO Sales Value Market Share by Country (2021-2026) Table 39. Global Life Science CDMO Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global Life Science CDMO Sales Value Market Share by Country (2027-2032) Table 41. Lonza Group Company Information Table 42. Lonza Group Business Overview Table 43. Lonza Group Life Science CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. Lonza Group Life Science CDMO Product Portfolio Table 45. Lonza Group Recent Development Table 46. Thermo Fisher Scientific Company Information Table 47. Thermo Fisher Scientific Business Overview Table 48. Thermo Fisher Scientific Life Science CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. Thermo Fisher Scientific Life Science CDMO Product Portfolio Table 50. Thermo Fisher Scientific Recent Development Table 51. Catalent Company Information Table 52. Catalent Business Overview Table 53. Catalent Life Science CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. Catalent Life Science CDMO Product Portfolio Table 55. Catalent Recent Development Table 56. WuXi Biologics Company Information Table 57. WuXi Biologics Business Overview Table 58. WuXi Biologics Life Science CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. WuXi Biologics Life Science CDMO Product Portfolio Table 60. WuXi Biologics Recent Development Table 61. Samsung Biologics Company Information Table 62. Samsung Biologics Business Overview Table 63. Samsung Biologics Life Science CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. Samsung Biologics Life Science CDMO Product Portfolio Table 65. Samsung Biologics Recent Development Table 66. Siegfried Company Information Table 67. Siegfried Business Overview Table 68. Siegfried Life Science CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Siegfried Life Science CDMO Product Portfolio Table 70. Siegfried Recent Development Table 71. Fujifilm Diosynth Biotechnologies Company Information Table 72. Fujifilm Diosynth Biotechnologies Business Overview Table 73. Fujifilm Diosynth Biotechnologies Life Science CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Fujifilm Diosynth Biotechnologies Life Science CDMO Product Portfolio Table 75. Fujifilm Diosynth Biotechnologies Recent Development Table 76. Lars Petersen Company Information Table 77. Lars Petersen Business Overview Table 78. Lars Petersen Life Science CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Lars Petersen Life Science CDMO Product Portfolio Table 80. Lars Petersen Recent Development Table 81. Recipharm Company Information Table 82. Recipharm Business Overview Table 83. Recipharm Life Science CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Recipharm Life Science CDMO Product Portfolio Table 85. Recipharm Recent Development Table 86. Boehringer Ingelheim Company Information Table 87. Boehringer Ingelheim Business Overview Table 88. Boehringer Ingelheim Life Science CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Boehringer Ingelheim Life Science CDMO Product Portfolio Table 90. Boehringer Ingelheim Recent Development Table 91. MilliporeSigma Company Information Table 92. MilliporeSigma Business Overview Table 93. MilliporeSigma Life Science CDMO Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 94. MilliporeSigma Life Science CDMO Product Portfolio Table 95. MilliporeSigma Recent Development Table 96. Aenova Group Company Information Table 97. Aenova Group Business Overview Table 98. Aenova Group Life Science CDMO Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 99. Aenova Group Life Science CDMO Product Portfolio Table 100. Aenova Group Recent Development Table 101. AGC Parma Chemicals Company Information Table 102. AGC Parma Chemicals Business Overview Table 103. AGC Parma Chemicals Life Science CDMO Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 104. AGC Parma Chemicals Life Science CDMO Product Portfolio Table 105. AGC Parma Chemicals Recent Development Table 106. GenScript Company Information Table 107. GenScript Business Overview Table 108. GenScript Life Science CDMO Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 109. GenScript Life Science CDMO Product Portfolio Table 110. GenScript Recent Development Table 111. Novartis Company Information Table 112. Novartis Business Overview Table 113. Novartis Life Science CDMO Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 114. Novartis Life Science CDMO Product Portfolio Table 115. Novartis Recent Development Table 116. Sai Life Sciences Company Information Table 117. Sai Life Sciences Business Overview Table 118. Sai Life Sciences Life Science CDMO Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 119. Sai Life Sciences Life Science CDMO Product Portfolio Table 120. Sai Life Sciences Recent Development Table 121. Research Programs/Design for This Report Table 122. Authors List of This Report Table 123. Secondary Sources Table 124. Primary Sources List of Figures Figure 1. Life Science CDMO Product Image Figure 2. Global Life Science CDMO Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Life Science CDMO Market Size (2021-2032) & (US$ Million) Figure 4. Global Life Science CDMO Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Active Pharmaceutical Ingredient (API) CDMO Image Figure 8. Biologics CDMO Image Figure 9. Finished Dosage Form (FDF) CDMO Image Figure 10. Others Image Figure 11. Global Life Science CDMO Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global Life Science CDMO Sales Value Share 2021 VS 2025 VS 2032 Figure 13. Global Life Science CDMO Sales Value Share by Type (2021-2032) Figure 14. Pharmaceutical Image Figure 15. Clinical Image Figure 16. Research Image Figure 17. Global Life Science CDMO Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Life Science CDMO Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Life Science CDMO Sales Value Share by Application (2021-2032) Figure 20. Global Life Science CDMO Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global Life Science CDMO Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America Life Science CDMO Sales Value (2021-2032) & (US$ Million) Figure 23. North America Life Science CDMO Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe Life Science CDMO Sales Value (2021-2032) & (US$ Million) Figure 25. Europe Life Science CDMO Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific Life Science CDMO Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific Life Science CDMO Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America Life Science CDMO Sales Value (2021-2032) & (US$ Million) Figure 29. South America Life Science CDMO Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa Life Science CDMO Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa Life Science CDMO Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA Life Science CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA Life Science CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA Life Science CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada Life Science CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada Life Science CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada Life Science CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico Life Science CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico Life Science CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico Life Science CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany Life Science CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany Life Science CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany Life Science CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France Life Science CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France Life Science CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France Life Science CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. Life Science CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. Life Science CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. Life Science CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy Life Science CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy Life Science CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy Life Science CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain Life Science CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain Life Science CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain Life Science CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia Life Science CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia Life Science CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia Life Science CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands Life Science CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands Life Science CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands Life Science CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries Life Science CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries Life Science CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries Life Science CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China Life Science CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China Life Science CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China Life Science CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan Life Science CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan Life Science CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan Life Science CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea Life Science CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea Life Science CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea Life Science CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India Life Science CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India Life Science CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India Life Science CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia Life Science CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia Life Science CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia Life Science CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia Life Science CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia Life Science CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia Life Science CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil Life Science CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil Life Science CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil Life Science CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina Life Science CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina Life Science CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina Life Science CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile Life Science CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile Life Science CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile Life Science CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia Life Science CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia Life Science CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia Life Science CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru Life Science CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru Life Science CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru Life Science CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Life Science CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia Life Science CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Life Science CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel Life Science CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel Life Science CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel Life Science CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE Life Science CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE Life Science CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE Life Science CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey Life Science CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey Life Science CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey Life Science CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran Life Science CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran Life Science CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran Life Science CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt Life Science CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt Life Science CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt Life Science CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • Active Pharmaceutical Ingredient (API) CDMO
  • Biologics CDMO
  • Finished Dosage Form (FDF) CDMO
  • Others
Applications
  • Pharmaceutical
  • Clinical
  • Research
Companies covered
  • Lonza Group
  • Thermo Fisher Scientific
  • Catalent
  • WuXi Biologics
  • Samsung Biologics
  • Siegfried
  • Fujifilm Diosynth Biotechnologies
  • Lars Petersen
  • Recipharm
  • Boehringer Ingelheim
  • MilliporeSigma
  • Aenova Group
  • AGC Parma Chemicals
  • GenScript
  • Novartis
  • Sai Life Sciences

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Life Science CDMO Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Life Science CDMO Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Life Science CDMO Market Dynamics
  1. 2.1 Life Science CDMO Industry Trends
  2. 2.2 Life Science CDMO Industry Drivers
  3. 2.3 Life Science CDMO Industry Opportunities and Challenges
  4. 2.4 Life Science CDMO Industry Restraints
3 Life Science CDMO Market by Company
  1. 3.1 Global Life Science CDMO Company Revenue Ranking in 2025
  2. 3.2 Global Life Science CDMO Revenue by Company (2021-2026)
  3. 3.3 Global Life Science CDMO Company Ranking (2024-2026)
  4. 3.4 Global Life Science CDMO Company Manufacturing Base and Headquarters
  5. 3.5 Global Life Science CDMO Company Product Type and Application
  6. 3.6 Global Life Science CDMO Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Life Science CDMO Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Life Science CDMO Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Life Science CDMO Market by Type
  1. 4.1 Life Science CDMO Type Introduction
  2. 4.1.1 Active Pharmaceutical Ingredient (API) CDMO
  3. 4.1.2 Biologics CDMO
  4. 4.1.3 Finished Dosage Form (FDF) CDMO
  5. 4.1.4 Others
  6. 4.2 Global Life Science CDMO Sales Value by Type
  7. 4.2.1 Global Life Science CDMO Sales Value by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Life Science CDMO Sales Value by Type (2021-2032)
  9. 4.2.3 Global Life Science CDMO Sales Value Share by Type (2021-2032)
5 Life Science CDMO Market by Application
  1. 5.1 Life Science CDMO Application Introduction
  2. 5.1.1 Pharmaceutical
  3. 5.1.2 Clinical
  4. 5.1.3 Research
  5. 5.2 Global Life Science CDMO Sales Value by Application
  6. 5.2.1 Global Life Science CDMO Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Life Science CDMO Sales Value by Application (2021-2032)
  8. 5.2.3 Global Life Science CDMO Sales Value Share by Application (2021-2032)
6 Life Science CDMO Regional Value Analysis
  1. 6.1 Global Life Science CDMO Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Life Science CDMO Sales Value by Region (2021-2032)
  3. 6.2.1 Global Life Science CDMO Sales Value by Region: 2021-2026
  4. 6.2.2 Global Life Science CDMO Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Life Science CDMO Sales Value (2021-2032)
  7. 6.3.2 North America Life Science CDMO Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Life Science CDMO Sales Value (2021-2032)
  10. 6.4.2 Europe Life Science CDMO Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Life Science CDMO Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Life Science CDMO Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Life Science CDMO Sales Value (2021-2032)
  16. 6.6.2 South America Life Science CDMO Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Life Science CDMO Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Life Science CDMO Sales Value Share by Country, 2025 VS 2032
7 Life Science CDMO Country-level Value Analysis
  1. 7.1 Global Life Science CDMO Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Life Science CDMO Sales Value by Country (2021-2032)
  3. 7.2.1 Global Life Science CDMO Sales Value by Country (2021-2026)
  4. 7.2.2 Global Life Science CDMO Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Life Science CDMO Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Life Science CDMO Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Life Science CDMO Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Life Science CDMO Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Life Science CDMO Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Life Science CDMO Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Life Science CDMO Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Life Science CDMO Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Life Science CDMO Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Life Science CDMO Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Life Science CDMO Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Life Science CDMO Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Life Science CDMO Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Life Science CDMO Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Life Science CDMO Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Life Science CDMO Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Life Science CDMO Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Life Science CDMO Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Life Science CDMO Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Life Science CDMO Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Life Science CDMO Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Life Science CDMO Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Life Science CDMO Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Life Science CDMO Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Life Science CDMO Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Life Science CDMO Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Life Science CDMO Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Life Science CDMO Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Life Science CDMO Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Life Science CDMO Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Life Science CDMO Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Life Science CDMO Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Life Science CDMO Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Life Science CDMO Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Life Science CDMO Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Life Science CDMO Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Life Science CDMO Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Life Science CDMO Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Life Science CDMO Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Life Science CDMO Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Life Science CDMO Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Life Science CDMO Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Life Science CDMO Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Life Science CDMO Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Life Science CDMO Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Life Science CDMO Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Life Science CDMO Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Life Science CDMO Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Life Science CDMO Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Life Science CDMO Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Life Science CDMO Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Life Science CDMO Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Life Science CDMO Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Life Science CDMO Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Life Science CDMO Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Life Science CDMO Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Life Science CDMO Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Life Science CDMO Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Life Science CDMO Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Life Science CDMO Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Life Science CDMO Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Life Science CDMO Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Life Science CDMO Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Life Science CDMO Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Life Science CDMO Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Life Science CDMO Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Life Science CDMO Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Life Science CDMO Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Life Science CDMO Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Life Science CDMO Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Life Science CDMO Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Life Science CDMO Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Life Science CDMO Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Life Science CDMO Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Life Science CDMO Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Life Science CDMO Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Life Science CDMO Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Life Science CDMO Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Life Science CDMO Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Life Science CDMO Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Life Science CDMO Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Life Science CDMO Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Life Science CDMO Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Life Science CDMO Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Lonza Group
  2. 8.1.1 Lonza Group Company Information
  3. 8.1.2 Lonza Group Business Overview
  4. 8.1.3 Lonza Group Life Science CDMO Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Lonza Group Life Science CDMO Product Portfolio
  6. 8.1.5 Lonza Group Recent Developments
  7. 8.2 Thermo Fisher Scientific
  8. 8.2.1 Thermo Fisher Scientific Company Information
  9. 8.2.2 Thermo Fisher Scientific Business Overview
  10. 8.2.3 Thermo Fisher Scientific Life Science CDMO Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Thermo Fisher Scientific Life Science CDMO Product Portfolio
  12. 8.2.5 Thermo Fisher Scientific Recent Developments
  13. 8.3 Catalent
  14. 8.3.1 Catalent Company Information
  15. 8.3.2 Catalent Business Overview
  16. 8.3.3 Catalent Life Science CDMO Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Catalent Life Science CDMO Product Portfolio
  18. 8.3.5 Catalent Recent Developments
  19. 8.4 WuXi Biologics
  20. 8.4.1 WuXi Biologics Company Information
  21. 8.4.2 WuXi Biologics Business Overview
  22. 8.4.3 WuXi Biologics Life Science CDMO Revenue and Gross Margin (2021-2026)
  23. 8.4.4 WuXi Biologics Life Science CDMO Product Portfolio
  24. 8.4.5 WuXi Biologics Recent Developments
  25. 8.5 Samsung Biologics
  26. 8.5.1 Samsung Biologics Company Information
  27. 8.5.2 Samsung Biologics Business Overview
  28. 8.5.3 Samsung Biologics Life Science CDMO Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Samsung Biologics Life Science CDMO Product Portfolio
  30. 8.5.5 Samsung Biologics Recent Developments
  31. 8.6 Siegfried
  32. 8.6.1 Siegfried Company Information
  33. 8.6.2 Siegfried Business Overview
  34. 8.6.3 Siegfried Life Science CDMO Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Siegfried Life Science CDMO Product Portfolio
  36. 8.6.5 Siegfried Recent Developments
  37. 8.7 Fujifilm Diosynth Biotechnologies
  38. 8.7.1 Fujifilm Diosynth Biotechnologies Company Information
  39. 8.7.2 Fujifilm Diosynth Biotechnologies Business Overview
  40. 8.7.3 Fujifilm Diosynth Biotechnologies Life Science CDMO Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Fujifilm Diosynth Biotechnologies Life Science CDMO Product Portfolio
  42. 8.7.5 Fujifilm Diosynth Biotechnologies Recent Developments
  43. 8.8 Lars Petersen
  44. 8.8.1 Lars Petersen Company Information
  45. 8.8.2 Lars Petersen Business Overview
  46. 8.8.3 Lars Petersen Life Science CDMO Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Lars Petersen Life Science CDMO Product Portfolio
  48. 8.8.5 Lars Petersen Recent Developments
  49. 8.9 Recipharm
  50. 8.9.1 Recipharm Company Information
  51. 8.9.2 Recipharm Business Overview
  52. 8.9.3 Recipharm Life Science CDMO Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Recipharm Life Science CDMO Product Portfolio
  54. 8.9.5 Recipharm Recent Developments
  55. 8.10 Boehringer Ingelheim
  56. 8.10.1 Boehringer Ingelheim Company Information
  57. 8.10.2 Boehringer Ingelheim Business Overview
  58. 8.10.3 Boehringer Ingelheim Life Science CDMO Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Boehringer Ingelheim Life Science CDMO Product Portfolio
  60. 8.10.5 Boehringer Ingelheim Recent Developments
  61. 8.11 MilliporeSigma
  62. 8.11.1 MilliporeSigma Company Information
  63. 8.11.2 MilliporeSigma Business Overview
  64. 8.11.3 MilliporeSigma Life Science CDMO Revenue and Gross Margin (2021-2026)
  65. 8.11.4 MilliporeSigma Life Science CDMO Product Portfolio
  66. 8.11.5 MilliporeSigma Recent Developments
  67. 8.12 Aenova Group
  68. 8.12.1 Aenova Group Company Information
  69. 8.12.2 Aenova Group Business Overview
  70. 8.12.3 Aenova Group Life Science CDMO Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Aenova Group Life Science CDMO Product Portfolio
  72. 8.12.5 Aenova Group Recent Developments
  73. 8.13 AGC Parma Chemicals
  74. 8.13.1 AGC Parma Chemicals Company Information
  75. 8.13.2 AGC Parma Chemicals Business Overview
  76. 8.13.3 AGC Parma Chemicals Life Science CDMO Revenue and Gross Margin (2021-2026)
  77. 8.13.4 AGC Parma Chemicals Life Science CDMO Product Portfolio
  78. 8.13.5 AGC Parma Chemicals Recent Developments
  79. 8.14 GenScript
  80. 8.14.1 GenScript Company Information
  81. 8.14.2 GenScript Business Overview
  82. 8.14.3 GenScript Life Science CDMO Revenue and Gross Margin (2021-2026)
  83. 8.14.4 GenScript Life Science CDMO Product Portfolio
  84. 8.14.5 GenScript Recent Developments
  85. 8.15 Novartis
  86. 8.15.1 Novartis Company Information
  87. 8.15.2 Novartis Business Overview
  88. 8.15.3 Novartis Life Science CDMO Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Novartis Life Science CDMO Product Portfolio
  90. 8.15.5 Novartis Recent Developments
  91. 8.16 Sai Life Sciences
  92. 8.16.1 Sai Life Sciences Company Information
  93. 8.16.2 Sai Life Sciences Business Overview
  94. 8.16.3 Sai Life Sciences Life Science CDMO Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Sai Life Sciences Life Science CDMO Product Portfolio
  96. 8.16.5 Sai Life Sciences Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst